FacebookTwitterRedditEmail

Opioids for Depression? Not So Fast Says An FDA Advisory Committee

Photo Source Cindy Shebley | CC BY 2.0

The mental illness “franchise” has been very good to Pharma. While it could not “grow” the number of people with actual schizophrenia, it hassuccessfully grown those diagnosed with amorphous “schizoaffective” and bipolar disorders and, of course, depression.

Thanks to Pharma’s everyone-is-mentally-ill ploy, buoyed by the Pharma-funded writers of the Diagnostic and Statistical Manual of Mental Disorders, an estimated one quarter of the population now takes psych drugs. Gone are the days when bad moods were attributed to problems with finance, romance, jobs, housing, family, marriages and health.

Especially lucrative to Pharma is its concoction of “treatment resistant” depression which allows expensive psych drugs to be added to antidepressants while side-stepping why the aggressively advertised SSRIs aren’t effective on their own. (And whether the patient was ever really depressed.) The resulting “cocktails” are exceedingly hard for patients to quit––with new drugs added to treat the side effects of other drugs––and what is the original “mental illness” versus the drug effects is almost impossible to distinguish. Adding expensive psych drugs for “treatment resistant” depression has become such a common, profitable practice for Pharma, prescribing only one drug is now dismissed as just “monotherapy.”

The latest attempt to cash in on “treatment resistant” depression is by the Dublin-based biopharma company Alkermes. It hopes to jump start revenues with a “treatment resistant” depression drug candidate that combines the opioid buprenorphine (used to treat opioid addiction) with samidorphan, an opioid blocker to counteract the abuse potential of buprenorphine.

In hearings on November 1, Alkermes representatives tried to sell their drug candidate against antipsychotic drugs currently FDA-approved to be added for “treatment resistant” depression like quetiapine (Seroquel) and aripiprazole (Abilify) because those drugs add weight in patients and opioids don’t.

But Alkermes’ “two wrongs make a right” argument convinced few at the hearings in the middle of our current opioid addiction epidemic which takes over a hundred lives a day. All opioid drugs have abuse potential noted Stephanie Fox-Rawlings of National Center for Health Research during the open mike section and people with depression are especially prone to substance abuse.

Nor were advisory committee impressed with Alkermes’ effectiveness and safety data which was so weak it extrapolated positive results from only “one patient” observed a committee member and which used unaccepted, questionable study designs.

As always happens when new, expensive drug candidates come before an FDA advisory committee, Pharma was well represented by open mike speakers. In addition to those actually flown in and paid for by Alkermes, representatives from the Pharma-funded Depression & Bipolar Support Alliance and the Pharma-funded  American Foundation for Suicide Prevention made trite, tear-jerking pleas. Without a new buprenorphine/samidorphan drug, there will be more suicides ventured one speaker omitting the hundreds whose suicides are causedby psych drugs according to thousands of published reports.

If insurance doesn’t cover this new drug, patients who can’t afford it will suffer said another open mike speaker, exposing in one sentence how Pharma hijacks our health care costs with its 4 and 5-digit brand-name drug pricing racket.

However, despite the well-oiled Pharma game plan that gets expensive and often ineffective and unsafe drugs approved and the shameless Pharma plants, this FDA advisory committee decided in a 20-3 vote there was insufficient evidence that the new drug works. Normally the FDA follows its advisory committees decisions––let’s hope it does in this case.

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
September 19, 2019
Richard Falk
Burning Amazonia, Denying Climate Change, Devastating Syria, Starving Yemen, and Ignoring Kashmir
Charles Pierson
With Enemies Like These, Trump Doesn’t Need Friends
Lawrence Davidson
The Sorry State of the Nobel Peace Prize
Evaggelos Vallianatos
The Scourge in the White House
Urvashi Sarkar
“Not a Blade of Grass Grew:” Living on the Edge of the Climate Crisis in the Sandarbans of West Bengal.
Thomas Knapp
Trump and Netanyahu: “Mutual Defense” or Just Mutual Political Back-Scratching?
Dean Baker
Is There Any Lesser Authority Than Alan Greenspan?
Gary Leupp
Warren’s Ethnic Issue Should Not Go Away
George Ochenski
Memo to Trump: Water Runs Downhill
Jeff Cohen
What George Carlin Taught Us about Media Propaganda by Omission
Stephen Martin
The Perspicacity of Mcluhan and Panopticonic Plans of the MIC
September 18, 2019
Kenneth Surin
An Excellent Study Of The Manufactured Labour “Antisemitism Crisis”
Patrick Cockburn
The Saudi Crown Prince Plans to Make Us Forget About the Murder of Jamal Khashoggi Before the US Election
W. T. Whitney
Political Struggle and Fixing Cuba’s Economy
Ron Jacobs
Support the Climate Strike, Not a Military Strike
John Kendall Hawkins
Slouching Toward “Bethlehem”
Ted Rall
Once Again in Afghanistan, the U.S. Proves It Can’t Be Trusted
William Astore
The Ultra-Costly, Underwhelming F-35 Fighter
Dave Lindorff
Why on Earth Would the US Go to War with Iran over an Attack on Saudi Oil Refineries?
Binoy Kampmark
Doctored Admissions: the University Admissions Scandal as a Global Problem
Jeremy Corbyn
Creating a Society of Hope and Inclusion: Speech to the TUC
Zhivko Illeieff
Why You Should Care About #ShutDownDC and the Global Climate Strike  
Catherine Tumber
Land Without Bread: the Green New Deal Forsakes America’s Countryside
Liam Kennedy
Boris Johnson: Elitist Defender of Britain’s Big Banks
September 17, 2019
Mario Barrera
The Southern Strategy and Donald Trump
Robert Jensen
The Danger of Inspiration in a Time of Ecological Crisis
Dean Baker
Health Care: Premiums and Taxes
Dave Lindorff
Recalling the Hundreds of Thousands of Civilian Victims of America’s Endless ‘War on Terror’
Binoy Kampmark
Oiling for War: The Houthi Attack on Abqaiq
Susie Day
You Say You Want a Revolution: a Prison Letter to Yoko Ono
Rich Gibson
Seize Solidarity House
Laura Flanders
From Voice of America to NPR: New CEO Lansing’s Glass House
Don Fitz
What is Energy Denial?
Dan Bacher
Governor Newsom Says He Will Veto Bill Blocking Trump Rollback of Endangered Fish Species Protections
Thomas Knapp
Election 2020: Time to Stop Pretending and Start Over
W. Alejandro Sanchez
Inside the Syrian Peace Talks
Elliot Sperber
Mickey Mouse Networks
September 16, 2019
Sam Husseini
Biden Taking Iraq Lies to the Max
Paul Street
Joe Biden’s Answer to Slavery’s Legacy: Phonographs for the Poor
Paul Atwood
Why Mattis is No Hero
Jonathan Cook
Brexit Reveals Jeremy Corbyn to be the True Moderate
Jeff Mackler
Trump, Trade and China
Robert Hunziker
Fukushima’s Radioactive Water Crisis
Evaggelos Vallianatos
The Democrats and the Climate Crisis
Michael Doliner
Hot Stuff on the Afghan Peace Deal Snafu
FacebookTwitterRedditEmail